Incyte Corp. (INCY) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (93% profit margin, 42% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.
Incyte Corp. (INCY) slipped -0.06% to $116.80 as options desks priced 58% call premium vs. 42% put protection around the $114 max-pain magnet. High-quality cash engine (93% profit margin, 42% return on capital) with steady institutional support.
Incyte (NasdaqGS: INCY) and Adagene have started first patient dosing in a Phase 1 trial combining INCA33890 with muzastotug for microsatellite stable colorectal cancer. The early stage study is testing the investigation
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 14% year on year to $1.56 billion. On the other hand, the company’s full-year
S&P 500 gap movers on October 30, 2026 included FDXF, VLTO, GILD and INCY on the upside, while INTC, RDDT and TWLO were among the gap-down decliners.
Netflix initiated, Instacart upgraded: Wall Street's top analyst calls
Wells Fargo analyst Derek Archila maintains Incyte (NASDAQ:INCY) with a Equal-Weight and lowers the price target from $128 to $127.
RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $114 to $117.
Tech giants are rattling pre-market futures on Halloween Eve, and Wall Street analysts are scrambling to reprice everything from chipmakers to delivery apps. Find out which stocks just got upgraded despite the chaos and
Barclays analyst Etzer Darout maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $139 to $143.
Analysts upgraded Incyte, Intel, Rivian and Monolithic Power, raising ratings and targets; MPWR’s target increased to $1,700.
Evercore ISI Group analyst Maneka Mirchandaney maintains Incyte (NASDAQ:INCY) with a In-Line and raises the price target from $125 to $127.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +21.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on INCY today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for INCY. Explore sector supply chains on /butterfly.
Why INCY Stock slipped -0.06% Today — RQD Quant Desk Flash. High-quality cash engine (93% profit margin, 42% return on capital) with steady institutional support.